| Literature DB >> 35615535 |
Viktor A Zapol'skii1, Isabell Berneburg2, Ursula Bilitewski3, Melissa Dillenberger2, Katja Becker2, Stefan Jungwirth3, Aditya Shekhar3, Bastian Krueger1, Dieter E Kaufmann1.
Abstract
A series of 26 novel 1-(7-chloroquinolin-4-yl)-4-nitro-1H-pyrazoles bearing a dichloromethyl and an amino or thio moiety at C3 and C5 has been prepared in yields up to 72% from the reaction of 1,1-bisazolyl-, 1-azolyl-1-amino-, and 1-thioperchloro-2-nitrobuta-1,3-dienes with 7-chloro-4-hydrazinylquinoline. A new way for the formation of a pyrazole cycle from 3-methyl-2-(2,3,3-trichloro-1-nitroallylidene)oxazolidine (6) is also described. In addition, the antimalarial activity of the synthesized compounds has been evaluated in vitro against the protozoan malaria parasite Plasmodium falciparum. Notably, the 7-chloro-4-(5-(dichloromethyl)-4-nitro-3-(1H-1,2,4-triazol-1-yl)-1H-pyrazol-1-yl)quinoline (3b) and 7-chloro-4-(3-((4-chlorophenyl)thio)-5-(dichloromethyl)-4-nitro-1H-pyrazol-1-yl)quinoline (9e) inhibited the growth of the chloroquine-sensitive Plasmodium falciparum strain 3D7 with EC50 values of 0.2 ± 0.1 µM (85 ng/mL, 200 nM) and 0.2 ± 0.04 µM (100 ng/mL, 200 nM), respectively. Two compounds (3b and 10d) have also been tested for anti-SARS-CoV-2, antibacterial, and cytotoxic activity.Entities:
Keywords: 1H-pyrazoles; 2-nitroperchlorobutadiene; anti-SARS-CoV-2 activity; antimalarial activity; chloroquine; nucleophilic vinylic substitution
Year: 2022 PMID: 35615535 PMCID: PMC9112185 DOI: 10.3762/bjoc.18.54
Source DB: PubMed Journal: Beilstein J Org Chem ISSN: 1860-5397 Impact factor: 2.544
Figure 1The structures of chloroquine, hydroxychloroquine, and amodiaquine.
Scheme 1Synthesis of 3-azolylpyrazoles 3a–c.
Scheme 2Assumed mechanism for the formation of 1H-pyrazoles 3a–c.
Scheme 3Synthesis of 3-aminopyrazoles 5b–k and 5-aminopyrazoles 5a and 5l–o.
Scheme 4Orientation of nucleophilic attack of 7-chloro-4-hydrazinylquinoline on nitrobutadienes 4.
Scheme 5Synthesis of oxazolidine 6 and pyrazole 7.
Scheme 6A plausible mechanism for the formation of pyrazole 7.
Scheme 7Synthesis of pyrazoles 9 and sulfoxide 10d.
Scheme 8Synthesis of pyrazole 11.
EC50 values of newly synthesized inhibitors on P. falciparum 3D7.
| compound | EC50 [µM]a |
|
|
|
|
|
0.2 ± 0.1 |
|
|
0.2 ± 0.04 |
|
|
0.3 ± 0.1 |
|
|
0.34 ± 0.01 |
|
|
0.41 ± 0.1 |
|
|
0.44 ± 0.1 |
|
|
0.46 ± 0.1 |
|
|
0.46 ± 0.1 |
|
|
0.48 ± 0.1 |
|
|
0.52 ± 0.2 |
|
|
0.61 ± 0.2 |
|
|
0.83 ± 0.1 |
|
|
0.9 ± 0.2 |
|
|
0.97 ± 0.8 |
|
|
1.1 ± 0.04 |
|
|
1.1 ± 0.2 |
|
|
1.2 ± 0.2 |
|
|
1.27 ± 0.1 |
|
|
1.28 ± 0.2 |
|
|
1.34 ± 0.5 |
|
|
1.53 ± 0.4 |
|
|
1.82 ± 0.3 |
|
|
2.07 ± 0.3 |
|
|
2.1 ± 0.3 |
|
|
4.1 ± 1.0 |
|
|
nIb |
| AQc | 0.006 ± 0.001 |
aEC50 values were determined on P. falciparum 3D7 parasites using the SYBR Green I-based fluorescence assay. Values are expressed as mean ± SD from at least three independent determinations with different batches of inhibitors each including at least two measurements; bnI = no Inhibition; cAQ = amodiaquine.